DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
GS-9857 is an investigational drug.
There have been 14 clinical trials for GS-9857. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Hepatitis C, Infection, and Virus Diseases. The leading clinical trial sponsors are Gilead Sciences, University of Maryland, and Unity Health Care, Inc.
There are twenty-five US patents protecting this investigational drug and six hundred and fifty-six international patents.
Recent Clinical Trials for GS-9857
|Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study||Gilead Sciences||Phase 3|
|Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience||Gilead Sciences||Phase 2|
|Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA Experience||Unity Health Care, Inc.||Phase 2|
Top disease conditions for GS-9857
Top clinical trial sponsors for GS-9857
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GS-9857||Start Trial||Synthesis of an antiviral compound||GILEAD SCIENCES, INC. (Foster City, CA)||Start Trial|
|GS-9857||Start Trial||Combination formulation of two antiviral compounds||Gilead Pharmasset LLC (Foster City, CA)||Start Trial|
|GS-9857||Start Trial||Toll like receptor modulator compounds||GILEAD SCIENCES, INC. (Foster City, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|